
    
      An open-label trial designed to evaluate CG0070 + DDM in patients with NMIBC who have failed
      prior BCG therapy. Single treatment arm that will enroll up to 110 patients with carcinoma in
      situ with or without concomitant high-grade Ta or T1 papillary disease

      BCG failure is defined as a persistent or recurrent disease within 12 months of completion of
      adequate BCG therapy.
    
  